FDA reviewers were divided over Stealth's data before Barth drug approval

Stealth BioTherapeutics' approval for its Barth syndrome drug came despite nearly all of the FDA's clinical and biostatistics reviewers concluding that it shouldn’t reach the market, according to an extensive